NEWSROOM
Press Releases by Agendia
News
Press Releases
An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:
One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question. The Read More
Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint and BluePrint’s Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients
New data from the I-SPY 2 trial highlights residual cancer burden as a prognostic indicator for long-term outcomes in patients pre-selected using MammaPrint NBRST trial reports three-year patient outcomes showing that the use of MammaPrint Read More
Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint and BluePrint to Patients in Southeast Asia
Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and BluePrint® to personalize treatment management decisions for early breast cancer IRVINE, CA AND AMSTERDAM, NETHERLANDS – 24 Read More
Agendia’s MammaPrint and BluePrint Breast Cancer Tests Selected by Unicancer for French Patients
IRVINE, CA, AMSTERDAM, NETHERLANDS – 15 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the Read More
Agendia’s MammaPrint Receives Positive Coverage Decisions from Three Major Private Healthcare Insurers
Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of Clinical Oncology (ASCO) guidelines recommending MammaPrint® Breast Cancer Risk of Recurrence Test for certain breast cancer patients Majority of U.S. Read More
Agendia Announces CE Mark for NGS-Based MammaPrint BluePrint Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe
IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Read More
Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint BluePrint Breast Cancer Kit to Market
IRVINE, CA, AMSTERDAM, and RIJSWIJK, NETHERLANDS – 19 December 2017 – Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, and Bluebee, a company driving global genomic data-driven medicine, have partnered to Read More
